Literature DB >> 17085830

Expression of nestin--a stem cell associated intermediate filament in human CNS tumours.

Sandhya B Rani1, Anita Mahadevan, Shobha Rani Anilkumar, T R Raju, S K Shankar.   

Abstract

BACKGROUND &
OBJECTIVES: Nestin is an intermediate filament protein expressed in undifferentiated cells during the development of brain and is considered as a marker for neuroepithelial stem cells. Expression of this protein in various CNS tumour cells suggests the possibility of existence of tumour stem cell modulating the evolution. We carried out an immunohistochemical study to demonstrate the expression of nestin and its co-expression with neuronal and glial intermediate filament and correlate with the grade of malignancy.
METHODS: Formalin fixed, paraffin processed sections from two human foetuses, 16 brain tumours of both neuronal and glial lineage and two metastatic tumours were immunostained with polyclonal antibody to nestin. Serial sections from primary brain tumours were also stained with monoclonal antibody to neurofilament (NF) and glial fibrillary acidic protein (GFAP). Fluorescent double labeling was carried out on four cases using laser confocal microscopy, to document co-localization of nestin with other intermediate filaments in the tumour cells.
RESULTS: Nestin expression was observed along the paraventricular zone of human foetuses and in brain tumours of both glial and neuronal lineage, of both high and low grades of malignancy. In addition, mature dysplastic spinal motor neurons adjacent to tumour and cerebellar Purkinje cells also expressed nestin along with neurofilament. INTERPRETATION &
CONCLUSION: Nestin expression was noted in both low and high grade brain tumours and dysplastic neurons and did not parallel the malignant grade of the tumour. The expression of nestin in tumour cells and dysplastic neurons suggests aberrant expression of antigenically primitive proteins in cells to facilitate remodelling of the cell and migration. More studies are needed to elucidate the concept.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17085830

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  6 in total

1.  Expression of cancer stem cell markers and their correlation with pathogenesis in vascular tumors.

Authors:  Jiaojiao Lan; Bing Huang; Ruixue Liu; Xinxin Ju; Yang Zhou; Jinfang Jiang; Weihua Liang; Yaoyuan Shen; Feng Li; Lijuan Pang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Endogenous neural stem/progenitor cells stabilize the cortical microenvironment after traumatic brain injury.

Authors:  Kirsty J Dixon; Michelle H Theus; Claudiu M Nelersa; Jose Mier; Lissette G Travieso; Tzong-Shiue Yu; Steven G Kernie; Daniel J Liebl
Journal:  J Neurotrauma       Date:  2015-02-27       Impact factor: 5.269

3.  Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines.

Authors:  Renata Veselska; Marketa Hermanova; Tomas Loja; Petr Chlapek; Iva Zambo; Karel Vesely; Karel Zitterbart; Jaroslav Sterba
Journal:  BMC Cancer       Date:  2008-10-16       Impact factor: 4.430

4.  Role of the stem cell-associated intermediate filament nestin in malignant proliferation of non-small cell lung cancer.

Authors:  Zhenguang Chen; Jiancheng Wang; Lie Cai; Beilong Zhong; Honghe Luo; Yuantao Hao; Weihua Yu; Binchao Wang; Chunhua Su; Yiyan Lei; Amos Ela Bella; Andy Peng Xiang; Tao Wang
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

5.  Contribution of nestin positive esophageal squamous cancer cells on malignant proliferation, apoptosis, and poor prognosis.

Authors:  Beilong Zhong; Tao Wang; Zhenguang Chen; Xueping Lun; Jinli Zhang; Sannv Zheng; Weilin Yang; Weiqiang Li; Andy Peng Xiang
Journal:  Cancer Cell Int       Date:  2014-06-20       Impact factor: 5.722

6.  Nestin expression involves invasiveness of esophageal carcinoma and its downregulation enhances paclitaxel sensitivity to esophageal carcinoma cell apoptosis.

Authors:  Jinghang Zhang; Jiateng Zhong; Jian Yu; Jinsong Li; Wenyu Di; Ping Lu; Xiaoyu Yang; Weixing Zhao; Xianwei Wang; Wei Su
Journal:  Oncotarget       Date:  2017-05-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.